Cumulative Incidence of Cancer After Solid Organ Transplantation

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2013 Apr 6

PMID 23559438

Citations 59

Authors

Erin C Hall

Ruth M Pfeiffer

Dorry L Segev

Eric A Engels

Affiliations

Soon will be listed here.

Abstract

Background: Solid organ transplantation recipients have elevated cancer incidence. Estimates of absolute cancer risk after transplantation can inform prevention and screening.

Methods: The Transplant Cancer Match Study links the US transplantation registry with 14 state/regional cancer registries. The authors used nonparametric competing risk methods to estimate the cumulative incidence of cancer after transplantation for 2 periods (1987-1999 and 2000-2008). For recipients from 2000 to 2008, the 5-year cumulative incidence, stratified by organ, sex, and age at transplantation, was estimated for 6 preventable or screen-detectable cancers. For comparison, the 5-year cumulative incidence was calculated for the same cancers in the general population at representative ages using Surveillance, Epidemiology, and End Results data.

Results: Among 164,156 recipients, 8520 incident cancers were identified. The absolute cancer risk was slightly higher for recipients during the period from 2000 to 2008 than during the period from 1987 to 1999 (5-year cumulative incidence: 4.4% vs. 4.2%; P = .006); this difference arose from the decreasing risk of competing events (5-year cumulative incidence of death, graft failure, or retransplantation: 26.6% vs. 31.9%; P < .001). From 2000 to 2008, the 5-year cumulative incidence of non-Hodgkin lymphoma was highest at extremes of age, especially in thoracic organ recipients (ages 0-34 years: range, 1.74%-3.28%; aged >50 years; range, 0.36%-2.22%). For recipients aged >50 years, the 5-year cumulative incidence was higher for colorectal cancer (range, 0.33%-1.94%) than for the general population at the recommended screening age (aged 50 years: range, 0.25%-0.33%). For recipients aged >50 years, the 5-year cumulative incidence was high for lung cancer among thoracic organ recipients (range, 1.16%-3.87%) and for kidney cancer among kidney recipients (range, 0.53%-0.84%). The 5-year cumulative incidence for prostate cancer and breast cancer was similar or lower in transplantation recipients than at the recommended ages of screening in the general population.

Conclusions: Subgroups of transplantation recipients have a high absolute risk of some cancers and may benefit from targeted prevention or screening.

Citing Articles

Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia.

Gong X, Zhai X, Shen Q, Gale R, Chen J Leukemia. 2025; .

PMID: 40000844 DOI: 10.1038/s41375-025-02540-7.

Stereotactic Body Radiotherapy in a Transplanted Lung for a Primary Lung Cancer: Case Report.

Ferreira P, Maia D, Abdulrehman M Case Rep Oncol. 2025; 18(1):85-91.

PMID: 39980508 PMC: 11731908. DOI: 10.1159/000542713.

Malignancies After Lung Transplantation.

Stenman C, Wallinder A, Holmberg E, Karason K, Magnusson J, Dellgren G Transpl Int. 2024; 37:12127.

PMID: 39314925 PMC: 11417467. DOI: 10.3389/ti.2024.12127.

Malignancies After Heart Transplantation.

Stenman C, Wallinder A, Holmberg E, Karason K, Magnusson J, Dellgren G Transpl Int. 2024; 37:12109.

PMID: 39314924 PMC: 11417470. DOI: 10.3389/ti.2024.12109.

Ocular Surface Squamous Neoplasia in Renal Transplant Patients.

Kaplan A, Akalin T, Palamar M Beyoglu Eye J. 2024; 9(3):161-164.

PMID: 39239627 PMC: 11372405. DOI: 10.14744/bej.2024.79664.

References

Varadhan R, Weiss C, Segal J, Wu A, Scharfstein D, Boyd C . Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care. 2010; 48(6 Suppl):S96-105. DOI: 10.1097/MLR.0b013e3181d99107. View

. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151(10):716-26, W-236. DOI: 10.7326/0003-4819-151-10-200911170-00008. View

Grulich A, van Leeuwen M, Falster M, Vajdic C . Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581):59-67. DOI: 10.1016/S0140-6736(07)61050-2. View

Opelz G, Daniel V, Naujokat C, Dohler B . Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation. 2009; 88(8):962-7. DOI: 10.1097/TP.0b013e3181b9692d. View

Smith R, Cokkinides V, Brooks D, Saslow D, Brawley O . Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010; 60(2):99-119. DOI: 10.3322/caac.20063. View

Dickson R, Davis R, Rea J, Palmer S . High frequency of bronchogenic carcinoma after single-lung transplantation. J Heart Lung Transplant. 2006; 25(11):1297-301. PMC: 3693444. DOI: 10.1016/j.healun.2006.09.009. View

Traywick C, OReilly F . Management of skin cancer in solid organ transplant recipients. Dermatol Ther. 2005; 18(1):12-8. DOI: 10.1111/j.1529-8019.2005.05002.x. View

Kiberd B, Keough-Ryan T, Clase C . Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant. 2003; 3(5):619-25. DOI: 10.1034/j.1600-6143.2003.00118.x. View

Minai O, Shah S, Mazzone P, Budev M, Sahoo D, Murthy S . Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J Thorac Oncol. 2008; 3(12):1404-9. DOI: 10.1097/JTO.0b013e31818e1259. View

10.

. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 Suppl 3:S1-155. DOI: 10.1111/j.1600-6143.2009.02834.x. View

11.

Swerdlow A, Higgins C, Hunt B, Thomas J, Burke M, Crawford D . Risk of lymphoid neoplasia after cardiothoracic transplantation. a cohort study of the relation to Epstein-Barr virus. Transplantation. 2001; 69(5):897-904. DOI: 10.1097/00007890-200003150-00039. View

12.

Zwald F, Brown M . Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011; 65(2):263-279. DOI: 10.1016/j.jaad.2010.11.063. View

13.

Villeneuve P, Schaubel D, Fenton S, Shepherd F, Jiang Y, Mao Y . Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007; 7(4):941-8. DOI: 10.1111/j.1600-6143.2007.01736.x. View

14.

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

15.

Dharnidharka V, Lamb K, Gregg J, Meier-Kriesche H . Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant. 2012; 12(4):976-83. DOI: 10.1111/j.1600-6143.2011.03893.x. View

16.

. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149(9):627-37. DOI: 10.7326/0003-4819-149-9-200811040-00243. View

17.

Hofbauer G, Anliker M, Arnold A, Binet I, Hunger R, Kempf W . Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly. 2009; 139(29-30):407-15. DOI: 10.4414/smw.2009.12725. View

18.

Collett D, Mumford L, Banner N, Neuberger J, Watson C . Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010; 10(8):1889-96. DOI: 10.1111/j.1600-6143.2010.03181.x. View

19.

Harris N, Ferry J, Swerdlow S . Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997; 14(1):8-14. View

20.

Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck G . Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology. 1995; 195(3):667-71. DOI: 10.1148/radiology.195.3.7753991. View